Cargando…
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
Autores principales: | Hughes, Derralynn A., Deegan, Patrick, Giraldo, Pilar, Göker-Alpan, Özlem, Lau, Heather, Lukina, Elena, Revel-Vilk, Shoshana, Scarpa, Maurizio, Botha, Jaco, Gadir, Noga, Zimran, Ari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299381/ https://www.ncbi.nlm.nih.gov/pubmed/37373710 http://dx.doi.org/10.3390/jcm12124017 |
Ejemplares similares
-
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022) -
The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023) -
Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017) -
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2023) -
Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies
por: Wagner, Victoria F., et al.
Publicado: (2017)